Why the Cochrane risk of bias tool should not include funding source as a standard item

doi:10.1002/14651858.ED000076

Editorial

. 2013 Dec 20;2013(12):ED000076.

doi: 10.1002/14651858.ED000076.

Why the Cochrane risk of bias tool should not include funding source as a standard item

Jonathan Ac Sterne¹

Affiliations

PMID: 24575440
PMCID: PMC10897924
DOI: 10.1002/14651858.ED000076

Editorial

Why the Cochrane risk of bias tool should not include funding source as a standard item

Jonathan Ac Sterne. Cochrane Database Syst Rev. 2013.

. 2013 Dec 20;2013(12):ED000076.

doi: 10.1002/14651858.ED000076.

Author

Jonathan Ac Sterne¹

Affiliation

¹ School of Social and Community Medicine, University of Bristol, UK.

PMID: 24575440
PMCID: PMC10897924
DOI: 10.1002/14651858.ED000076

No abstract available

PubMed Disclaimer

Cited by

Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009.
Benea C, Turner KA, Roseman M, Bero LA, Lexchin J, Turner EH, Thombs BD. Benea C, et al. Syst Rev. 2020 Apr 8;9(1):77. doi: 10.1186/s13643-020-01318-5. Syst Rev. 2020. PMID: 32268911 Free PMC article.
Should clinical automated perimetry be considered for routine functional assessment of early/intermediate age-related macular degeneration (AMD)? A systematic review of current literature.
Trinh M, Kalloniatis M, Nivison-Smith L. Trinh M, et al. Ophthalmic Physiol Opt. 2022 Jan;42(1):161-177. doi: 10.1111/opo.12919. Epub 2021 Nov 29. Ophthalmic Physiol Opt. 2022. PMID: 34843120 Free PMC article.
Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study.
Turner K, Carboni-Jiménez A, Benea C, Elder K, Levis B, Boruff J, Roseman M, Bero L, Lexchin J, Turner EH, Benedetti A, Thombs BD. Turner K, et al. BMJ Open. 2020 May 11;10(5):e035633. doi: 10.1136/bmjopen-2019-035633. BMJ Open. 2020. PMID: 32398334 Free PMC article.
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. Storebø OJ, et al. Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Mar 27;3:CD009885. doi: 10.1002/14651858.CD009885.pub3. PMID: 26599576 Free PMC article. Updated.
The judgement of biases included in the category "other bias" in Cochrane systematic reviews of interventions: a systematic survey.
Babic A, Pijuk A, Brázdilová L, Georgieva Y, Raposo Pereira MA, Poklepovic Pericic T, Puljak L. Babic A, et al. BMC Med Res Methodol. 2019 Apr 11;19(1):77. doi: 10.1186/s12874-019-0718-8. BMC Med Res Methodol. 2019. PMID: 30971219 Free PMC article.

See all "Cited by" articles

References

1. Bero L. Why the Cochrane risk of bias tool should include funding source as a standard item [Editorial]. Cochrane Database of Systematic Reviews 2013;(12):ED000075. - PMC - PubMed
1. Gøtzsche PC. Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Health Care. London: Radcliffe Publishing, 2013.
1. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
1. Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. BMJ 2013;347:f7569. doi.org/10.1136/bmj.f7569 - PubMed
1. Cochrane Bias Methods Group. Assessing risk of bias in included studies. bmg.cochrane.org/assessing‐risk‐bias‐included‐studies (accessed on 18 December 2013)

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Bero L. Why the Cochrane risk of bias tool should include funding source as a standard item [Editorial]. Cochrane Database of Systematic Reviews 2013;(12):ED000075. - PMC - PubMed

[2] Bero L. Why the Cochrane risk of bias tool should include funding source as a standard item [Editorial]. Cochrane Database of Systematic Reviews 2013;(12):ED000075. - PMC - PubMed

[3] Gøtzsche PC. Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Health Care. London: Radcliffe Publishing, 2013.

[4] Gøtzsche PC. Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Health Care. London: Radcliffe Publishing, 2013.

[5] Goldacre B. Bad Pharma. London: Fourth Estate; 2012.

[6] Goldacre B. Bad Pharma. London: Fourth Estate; 2012.

[7] Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. BMJ 2013;347:f7569. doi.org/10.1136/bmj.f7569 - PubMed

[8] Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. BMJ 2013;347:f7569. doi.org/10.1136/bmj.f7569 - PubMed

[9] Cochrane Bias Methods Group. Assessing risk of bias in included studies. bmg.cochrane.org/assessing‐risk‐bias‐included‐studies (accessed on 18 December 2013)

[10] Cochrane Bias Methods Group. Assessing risk of bias in included studies. bmg.cochrane.org/assessing‐risk‐bias‐included‐studies (accessed on 18 December 2013)

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Why the Cochrane risk of bias tool should not include funding source as a standard item

Affiliation

Why the Cochrane risk of bias tool should not include funding source as a standard item

Author

Affiliation

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources